Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update
November 4, 2019 7:00 AM ESTJeuveau® Generated $13.2 Million in U.S. Net Revenue in Q3 2019; up from $2.3 Million in Q2 2019
J.E.T. Enrolled Accounts Drove 90% of Q3 Revenue
Jeuveau® Achieved Number Three Unit Share Position in the U.S. for Q3 20191
Nuceiva Approved in the European Union and Launched in Canada
NEWPORT BEACH, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today... More
